Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1858-1863

  Tandstad, T ^a   Cohn Cedermark, G ^b   Dahl, O ^c   Stierner, U ^d   Cavallin Stahl, E ^e   Bremnes, R M ^f   Klepp, O ^g  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF TROMSØ   (Norway)

^g lesund Hospital   (Norway)

Author keywords

Adjuvant chemotherapy; Clinical stage 1; Long term follow up; Risk adapted treatment; Testicular cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; VINBLASTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ARTICLE; CANCER INVASION; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; FOLLOW UP; HUMAN; ILEUS; INFECTION; LEUKOPENIA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROPATHY; NORWAY; PARALYTIC ILEUS; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; RISK REDUCTION; SALVAGE THERAPY; SWEDEN; TESTIS NONSEMINOMA CANCER; THROMBOCYTOPATHY;

EID: 77956104590     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq026     Document Type: Article

References (30)

1. Jacobsen R, Moller H, Thoresen SO et al. Trends in testicular cancer incidence in the Nordic countries, focusing on the recent decrease in Denmark. Int J Androl 2006; 29: 199-204.
2. Cancer Registry of Norway. Cancer in Norway 2007-Cancer incidence, mortality, survival and prevalence in Norway, Oslo, Norway: Cancer Registry of Norway 2008.
3. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J Clin Oncol 2006; 24: 5482-5492.
4. Klepp O, Olsson AM, Henrikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990; 8: 509-518.
5. Alexandre J, Fizazi K, Mahe C et al. Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001; 37: 576-582.
6. Gels ME, Hoekstra HJ, Sleijfer DT et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995; 13: 1188-1194.
7. Klepp O, Flodgren P, Maartman-Moe H et al. Early clinical stages (CS1, CS1Mk+ and CS2A) of non-seminomatous testis cancer. Value of pre- and postorchiectomy serum tumor marker information in prediction of retroperitoneal lymph node metastases. Swedish-Norwegian Testicular Cancer Project (SWENOTECA). Ann Oncol 1990; 1: 281-288.
8. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10: 1762-1768.
9. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
10. Klepp O, Dahl O, Flodgren P et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997; 33: 1038-1044.
11. Peckham MJ, McElwain TJ, Barrett A et al. Combined management of malignant teratoma of the testis. Lancet 1979; 2: 267-270.
12. Oliver RTD, Ong J, Ostrowski J et al. Radiotherapy, surveillance or platinum based adjuvant chemotherapy for stage 1 germ cell. Proc Am Soc Clin Oncol 1993; 12: 231.
13. Nichols CR, Breeden ES, Loehrer PJ et al. Secondary leukemia associated with standard dose etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85: 36-40.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Haugnes HS, Aass N, Fossa SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
16. Brydoy M, Fossa SD, Klepp O et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97: 1580-1588.
17. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
18. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997; 89: 1429-1439.
19. Travis LB, Andersson M, Gospodarowicz M et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000; 92: 1165-1171.
20. Le Deley MC, Leblanc T, Shamsaldin A et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 2003; 21: 1074-1081.
21. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a longterm complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523.
22. Sagstuen H, Aass N, Fossa SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23: 4980-4990.
23. Bohlen D, Borner M, Sonntag RW et al. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 1999; 161: 1148-1152.
24. Dearnaley DP, Fossa SD, Kaye SB et al. Adjuvant bleomycin, vincristine and cisplatin (BOP) for high-risk stage I non-seminomatous germ cell tumours: a prospective trial (MRC TE17). Br J Cancer 2005; 92: 2107-2113.
25. Aass N, Fossa SD, Otto F et al. Acute subjective morbidity after cisplatin-based combination chemotherapy in patients with testicular cancer: a prospective study. Radiother Oncol 1989; 14: 27-33.
26. Westermann DH, Schefer H, Thalmann GN et al. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 2008; 179: 163-166.
27. Gilbert DC, Norman AR, Nicholl J et al. Treating stage I nonseminomatous germ cell tumours with a single cycle of chemotherapy. BJU Int 2006; 98: 67-69.
28. Chevreau C, Mazerolles C, Soulie M et al. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 2004; 46: 209-214; discussion 14-15.
29. Pont J, Albrecht W, Postner G et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14: 441-448.
30. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14: 1106-1113.